Effects of Dapagliflozin on Obese Patients With Type 2 Diabetes: A Prospective Observational Study From Bangladesh
Cureus · 04.08.2025
DOI: 10.7759/cureus.89360 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 04.08.2025. Verfasst von Somya Binte Akhond und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Mukti Hospital, Cumilla, BGD. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder frequently associated with obesity, leading to increased risks of cardiovascular and renal complications. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has emerged as a promising therapeutic agent for improving glycemic control and promoting weight reduction. However, evaluating its safety and efficacy in obese T2DM patients remains essential, particularly in real-world clinical settings. This study aimed to assess the safety and efficacy of dapagliflozin in obese patients with type 2 diabetes mellitus (T2DM) by assessing adverse event profiles and the reduction in HbA1c levels over the treatment period. METHODOLOGY: This 12-month prospective, multicenter observational study was conducted from April 2023 to April 2024 at BIRDEM (Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders) General Hospital, Dhaka, and affiliated healthcare centers in Bangladesh. One thousand five hundred patients with type 2 diabetes mellitus and a body mass index (BMI) ≥30 kg/m² were consecutively enrolled from outpatient clinics. Eligibility was based on a confirmed diagnosis of type 2 diabetes and the recent initiation of dapagliflozin therapy. Patients received 5 mg or 10 mg of dapagliflozin daily, either as monotherapy or in combination with other antidiabetic agents. Physicians made all treatment decisions independently as part of routine clinical care. Clinical and laboratory data were extracted from medical records using a standardized case record form. Outcomes included changes in glycemic and lipid parameters at baseline, three, six, and 12 months, and the frequency of adverse events. Statistical analyses were performed using IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, NY), with statistical significance set at p < 0.05. RESULTS: The study showed a statistically significant reduction in mean glycated hemoglobin levels from 8.1 ± 1.7 at baseline to 7.3 ± 1.4 after six months of treatment (p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Mukti Hospital, Cumilla, BGD.
- Department of Surgery, Enam Medical College and Hospital, Dhaka, BGD.
- Department of Dermatology, Ashiyan Medical College and Hospital, Dhaka, BGD.
- Department of Medicine, Kabir's Healthcare Hospital, Dhaka, BGD.
- Department of Surgery, The Royal Private Hospital, Moulvibazar, BGD.
- Department of General Internal Medicine, Al-Reza General Hospital, Jamalpur, BGD.
Zitieren
APA
Akhond, S. B., Bupasha, J., Jannat, G. E., Sharmin, L., Sumon, M. N. H., Akhter, R., & Mahbub, F. (2025). Effects of Dapagliflozin on Obese Patients With Type 2 Diabetes: A Prospective Observational Study From Bangladesh. Cureus. https://doi.org/10.7759/cureus.89360
Vancouver
Akhond SB, Bupasha J, Jannat GE, Sharmin L, Sumon MNH, Akhter R, et al. Effects of Dapagliflozin on Obese Patients With Type 2 Diabetes: A Prospective Observational Study From Bangladesh. Cureus. 2025. doi:10.7759/cureus.89360
BibTeX
@article{Akhond2025,
author = {Akhond, Somya Binte and Bupasha, Jamila and Jannat, Gull E and Sharmin, Lubna and Sumon, Md Nazmul Hossain and Akhter, Ruma and Mahbub, Fahim},
title = {Effects of Dapagliflozin on Obese Patients With Type 2 Diabetes: A Prospective Observational Study From Bangladesh},
journal = {Cureus},
year = {2025},
doi = {10.7759/cureus.89360}
}
EUVIMED